TENM4 and breast carcinoma: In conclusion, despite the relative lack of data on TENM4, it is emerging as an appealing shared oncogene in different breast cancer subtypes and deserves further investigations that will likely validate its clinical relevance as a marker and immunotherapeutic target for more effective treatment of this still-fatal disease.